scholarly journals A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

2020 ◽  
Author(s):  
Cheol-Kyu Park ◽  
Hyun-Ju Cho ◽  
Yoo-Duk Choi ◽  
In-Jae Oh ◽  
Young-Chul Kim
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Tumor Dna ◽  
First Line Treatment

Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial

Lung Cancer ◽  
2013 ◽  
Vol 80 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Radj Gervais ◽  
Gilles Robinet ◽  
Christelle Clément-Duchêne ◽  
Fabrice Denis ◽  
Claude El Kouri ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document